Merck
HomeWebinarsAmorphous Formulations for Bioavailability Enhancement: Risks and Opportunities

Amorphous Formulations for Bioavailability Enhancement: Risks and Opportunities



WEBINAR

Solubility is a major challenge in the development of oral solid dosage forms. Amorphous formulation with polymeric solid dispersions has been the technology of choice to enhance solubility. However, this approach may have some downfalls with the ability to successfully stabilize compounds, especially poor glass former compounds with a high propensity to re-crystallize. This webinar will examine amorphous stability from a theoretical perspective in the context of polymeric solid dispersions and mesoporous silica formulations. Finally, recent data demonstrating the potential of mesoporous silica for superior amorphous stabilization of poor glass formers will be presented.

In this webinar, you will learn:

  • Why solubility is a critical consideration in the development of oral medication
  • How the amorphous form can enhance solubility and increase absorption
  • Why some molecules are at risk of re-crystallization with typical polymeric amorphous technologies
  • How mesoporous silica can reduce the risk of re-crystallization of poor glass formers

Speaker

Daniel Joseph Price, Ph.D.

Daniel Joseph Price, Ph.D.

Merck

Strategic Marketing Manager

Daniel Joseph Price is a strategic marketing manager for our portfolio of solubility enhancement excipients. Prior to his current role, Daniel was a Marie Curie Fellow, conducting research on solubility enhancement with amorphous formulations. Daniel is an active member of several academia/industrial consortia on the topics of innovation in oral solid dosage forms and has published extensively on the topic in peer-reviewed journals. Daniel has a B.S. and an M.S. in chemistry from the University of Leeds and a Ph.D. in pharmaceutical technology from Frankfurt Goethe University.